JSAM
PRAX icon

J. Safra Asset Management’s Praxis Precision Medicines PRAX Stock Holding History

J. Safra Asset Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.4K Buy
54
+36
+200% +$11.1K ﹤0.01% 318
2025
Q4 		$5.3K Buy
+18
New +$3.35K ﹤0.01% 414

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

J. Safra Asset Management's PRAX Position: Q1 2026 in Review

J. Safra Asset Management increased its Praxis Precision Medicines (PRAX) stake by 200% in Q1 2026, buying an estimated $11.1K and bringing the position to 54 shares worth $17.4K. The position accounts for ﹤0.01% of the portfolio, ranked #318.

J. Safra Asset Management first reported a position in PRAX in Q4 2025 and has held it in 2 quarters since. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • J. Safra Asset Management held 54 shares of Praxis Precision Medicines worth $17.4K as of Q1 2026.
  • J. Safra Asset Management bought 36 Praxis Precision Medicines shares in Q1 2026, an estimated $11.1K.
  • Praxis Precision Medicines made up ﹤0.01% of J. Safra Asset Management's portfolio in Q1 2026, its #318 holding.
  • J. Safra Asset Management first reported a position in Praxis Precision Medicines in Q4 2025 and has held it in 2 quarters since.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on J. Safra Asset Management's 13F filing for Q1 2026, filed 4 May 2026.